Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2008

View Archived Issues

Novel transglycosylase inhibitors with antibacterial activity discovered

Eisai updates Q3 progress

Intercell to develop tuberculosis vaccine formulated with adjuvant IC-31

FDA accepts Y's Therapeutics' IND application to conduct a phase I clinical trial of YSCMA

Fornix reports results from phase II/III AB0602 clinical study of Oralgen

DiaMedica reports positive results from preclinical study of DM-99

Pharmaxis to apply for MAA in Australia for Bronchitol for the treatment of bronchiectasis

Alvine initiates dosing in phase I clinical trial of ALV-003 for celiac disease

New therapeutic agents for urinary incontinence imparted in recent Takeda patents

Recent patents report new agents for neurological disorders

Novel analgesic agents described in recent patent literature

AstraZeneca announces creation of a new company Albireo

Biogen Idec and Cardiokine initiate a phase III study of lixivaptan

DelSite initiates production of clinical quantities of nasal powder bird flu vaccine

TorreyPines presents 2008 strategic plan for tezampanel, NGX-426, and NGX-267

Migenix provides pipeline update

Neuroprotective effects of lithium in preclinical and clinical studies of ALS

VRX-496 affects HIV replication in phase II trial

Activity of RDEA-806 less affected by human serum proteins than other NNRTIs

Improved body composition seen with tesamorelin in HIV-associated lipohypertrophy

FDA approves Abbott's Simcor, a combination therapy for cholesterol management

Vaccinex licenses human anti-interleukin-6 antibody to GlaxoSmithKline

JADO reports proof of concept with lipid raft modulator in atopic dermatitis patients

Canada approves Wellbutrin XL for prevention of seasonal major depressive illness

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...